Mosaic ImmunoEngineering is a nanotechnology-based immunotherapy company developing therapeutics and vaccines to positively impact the lives of patients and their families.

Free
Message: substantially identical with the original patent,shall constitute a continuation

I can see infringers taking the position that we amended the claims to avoid prior art which would therefore not meet the "substantially identical" test.

The Judge would also expect this.. this was plan #2 all along.. since plan #1 (invalidation, appears to have) failed.. Now whom decides who's right and how is that decided?

Share
New Message
Please login to post a reply